Navigation Links
New Oral Anticoagulants Markets
Date:3/25/2013

tion 88
4.1.7.1 Inhibitors of TXA2 Pathway 88
4.1.7.2 Inhibitors of P2Y12 88
4.1.7.3 PAR-1 Inhibitors 89
4.1.7.4 Phosphodiesterase Inhibitors 89
4.2 Antiplatelet Drugs 89
4.2.1 Aspirin 89
4.2.2 Aggrenox 90
4.2.3 Ticagrelor (Brilinta) 91
4.2.4 Clopidogrel (Plavix) 92
4.2.4.1 Indications and Usage 92
4.2.4.2 General Risk of Bleeding 93
4.2.5 Effient (Prasugrel) 96

5. Coagulation Assays 97
5.1 Clotting Assays 97
5.1.1 Chromogenic Methods 97
5.1.2 Prothrombin Time 97
5.1.3 Activated Partial Thromboplastin Time 97
5.1.4 Thrombin Time 97
5.1.5 Fibrinogen (Clauss Method) 97
5.1.6 Derived Fibrinogen 97
5.1.7 Antithrombin 97
5.1.8 Protein C 97
5.1.9 Protein S 98
5.1.10 Lupus Anticoagulants 98
5.1.11 ProC Global Assay and APC Resistance (APCR) 98
5.2 Influence of New Anticoagulants on Coagulation Assays 98

6. Disease Conditions Targeted by Anticoagulants 100
6.1 Cardiovascular Diseases 100
6.1.1 Stroke 100
6.1.2 Ischemic Stroke 101
6.1.3 Hemorragic Stroke 101
6.1.4 Subarachnoid Hemorrage 102
6.1.5 Global Incidence and Prevalence of Stroke 102
6.1.6 Incidence of Stroke in the U.S. 103
6.1.7 Mortality from Heart Disease and Stroke in Selected OECD Countries 106
6.1.8 Anticoagulants Used in the Treatment for Stroke 106
6.1.8.1 Heparin 106
6.1.8.2 Warfarin 107
6.1.9 Antiplatelets 107
6.1.9.1 Aspirin 107
6.1.9.2 Dipyridamole 107
6.1.9.3 Clopidogrel 107
6.1.10 Transient Ischemic Attack (Mini Stroke) 107
6.1.10.1 Drug Therapy for Mini Stroke 108
6.1.11 Market for Stroke Medication 108
6.2 Cardiac Arrhythmia 109
6.2.1 Tachycardias 109
6.2.2 Bradycardias 111
6.2.3 Medications for Arrhythmias 111
6.2.4 Anticoagulants Used to Treat Arrhythmias 111
6.2.5 Global Market for Atrial Fibrillation Drugs 111
6.2.6 Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation 112'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Global Anticoagulants Industry
2. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
3. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
4. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
5. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
6. MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016
7. Transdermal Hormone Replacement: Products, Players, Markets and Forecasts
8. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
9. Global Market for Medical Imaging Equipment to Reach $25.3 Billion as Retiring Boomers and Emerging Markets Demand Better Healthcare
10. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
11. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... inflammatory disease and neurologic disorders, announced today the results ... citrate, the Company,s lead compound. Results from the study ... can significantly inhibit the activation of inflammatory proteins in ... this compound in a Phase 1 clinical trial under ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
(Date:6/30/2015)... Scotland , July 1, 2015 ... joins Nu C ana team   ... ProTide technology to develop and commercialise a portfolio of ... Chris McGuigan as Chief Scientific Officer. ... ProTide technology. He is currently Professor of Medicinal Chemistry ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3
... Amgen (Nasdaq: AMGN ), today announced the ... privately held biotechnology company based in Woburn, Mass., with ... a novel investigational oncolytic vaccine in Phase 3 clinical ... melanoma and head and neck cancer. The acquisition was ...
... , a leader in bioinformatics software and knowledge integration, ... license for Pathway Studio ® Enterprise system that ... MedScan® text processing technology for site-wide use. Pathway Studio ... pathways and develop mechanistic rationale for disease based on ...
Cached Medicine Technology:Amgen Completes Acquisition of BioVex 2Amgen Completes Acquisition of BioVex 3Amgen Completes Acquisition of BioVex 4Site-wide License for Ariadne's Pathway Studio Renewed by NCI 2
(Date:7/1/2015)... Tenn. (PRWEB) , ... July 01, 2015 , ... The ... held rain or shine Saturday, July 11, 2015, at 6 p.m. in Pugh Bourne ... free and includes pony rides, a petting zoo, an Elvis impersonator, a silent auction ...
(Date:7/1/2015)... Miami, Florida (PRWEB) , ... July 01, 2015 ... ... effects for society,” said lead author Lisa Stolzenberg, a Professor in FIU’s School ... on juveniles aged 12 to 17 years who participated in the National Survey ...
(Date:7/1/2015)... ... July 01, 2015 , ... Element Blue ™, ... today that it has received trademark protection for its SensorInsight® computer software platform. ... data from multiple sources providing an environment where users can view and compare ...
(Date:7/1/2015)... San Luis Obispo, CA (PRWEB) , ... July ... ... in non-surgical bunion treatment, announces their big summer sale. Customers purchasing two ... $15 with promo code "Summer15". , Bunion Bootie temporarily corrects misaligned ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... healthcare providers, has been retained to lead a national chief executive officer ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
Breaking Medicine News(10 mins):Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3
... the birth,of a daughter to 17-year-old actress Jamie Lynn ... issued the following,statement from CEO Sarah Brown:, "Every ... Jamie Lynn,Spears, new daughter, Maddie Briann, will be surrounded ... that is sure to now erupt, as it,did when ...
... Federal Reserve chairman Ben Bernanke,s,comments this week that ... one of the biggest challenges facing the nation, plus ... rise nearly 10 percent this,year, lend strong support to ... wellness, according to U.S. Preventive Medicine, the leader,in disease ...
... Cohera Medical Inc. today announced,that data published in ... the company,s surgical adhesive, TissuGlu, was effective in ... model., Summarized in a paper titled "Lysine-Derived ... Abdominoplasty Model," (Plast.,Reconstr. Surg. 2008; Vol. 122, Issue ...
... working to develop inexpensive paper that can destroy, deactivate ... will share their expertise with the world as the ... next week in Espoo, Finland. More than 80 science, ... will meet in the city northwest of Helsinki for ...
... proposes $2.29 billion hospice rate,cut, WASHINGTON, ... providers representing all 50 states are calling ... the Administration from slashing,the hospice reimbursement under ... millions of Americans nearing the end of,their ...
... The plant, Kalanchoe fedtschenkoi, is unique because, unlike normal plants, ... the air is cooler and more humid, making it 10 ... Scientists will use the latest next-generation DNA sequencing to analyse ... at night. , The project will generate a genome ...
Cached Medicine News:Health News:National Campaign to Prevent Teen and Unplanned Pregnancy Statement on Jamie Lynn Spears 2Health News:U.S. Preventive Medicine Views Bernanke's Comments as Strong Support for Prevention and Wellness Programs 2Health News:Data Published in Plastic and Reconstructive Surgery Show Cohera Medical's Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model 2Health News:Data Published in Plastic and Reconstructive Surgery Show Cohera Medical's Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model 3Health News:World research leaders gather in Finland to accelerate the development of bioactive paper 2Health News:Hospice Programs Nationwide Urge Congress to Act on Behalf of End-of Life Patients 2
... OmniMD Medical Billing system allows a ... accounting. It is integrated with the ... The system interfaces with electronic clearinghouses ... With a set of reports, it ...
... CPNG3 single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... CPNG3 reagent provides a long shelf ...
... Infinity Uric Acid single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Uric Acid reagent provides a ...
... Oxidase single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... Oxidase reagent provides a long shelf ...
Medicine Products: